The journey from a groundbreaking medical technology innovation to widespread patient access is fraught with peril. For many biotech and medtech startups, this 'Valley of Death' often lies between suc...
The journey from a groundbreaking medical technology innovation to widespread patient access is fraught with peril. For many biotech and medtech startups, this 'Valley of Death' often lies between successful pre-clinical development and securing regulatory approval for commercialization. A critical early step across this chasm is the successful completion of First-in-Human (FIH) clinical trials. While traditional markets present significant hurdles, Latin America offers a strategic, cost-effective, and efficient pathway to mitigate the Medtech Valley of Death for FIH studies. At bioaccess®, we specialize in guiding innovators through the complex landscape of clinical trials and regulatory affairs in Latin America. Our deep understanding of local regulations, patient populations, and logistical nuances positions us as your essential partner in bringing transformative medical technologies to market. This article explores how conducting your FIH studies in Latin America can be a game-cha…